Treating Disease Progression with Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: Novel Targeted Agents and Combination Strategies

In this review, the post-osimertinib treatment options for EGFR-mutated non-small-cell lung cancer are analyzed, with an outlook to ongoing clinical trials.